STAAR Surgical Company (STAA) stock analysis
Healthcare · Medical Instruments & Supplies
From the 10-K filed 2026-03-03
Business type: Asset play
How it makes money
It sells proprietary implantable lenses to medical distributors and surgeons, with results driven primarily by patient demand in regional markets like China.
The company focuses entirely on refractive eye surgery. It generates revenue by selling its 'Implantable Collamer Lenses' (ICLs), which are phakic lenses implanted into the eye to correct vision without removing the natural crystalline lens.
Because it relies on elective, premium procedures, profitability is sensitive to consumer spending patterns. When patient demand fluctuates in major regions, distributors adjust their bulk purchase volumes, which directly impacts the company's reported revenue.
What protects it: the moat
It relies on a proprietary material called Collamer to differentiate its lenses, though it faces broad competition in the refractive surgery market.
The company asserts that its ICLs are unique because they are made of Collamer, a collagen copolymer. This material is designed to be biocompatible, allowing for soft and flexible lenses that can be inserted through small incisions.
While the company claims this material is proprietary and exclusively used by them, it operates in a competitive industry where other refractive procedures exist. Management notes that growth and profitability are challenged by these competitive pressures.
What growth costs
It invests in surgeon training, market expansion, and manufacturing infrastructure to support the adoption of its lens portfolio.
Growth depends on increasing awareness of the ICL procedure and ensuring surgeons are trained to perform the surgery. The company also commits capital to expanding its manufacturing capacity, notably in Switzerland, and maintaining R&D labs to refine its product offerings.
These activities require ongoing discretionary spending. When sales growth slows, the company may be required to cut costs and realign its operations to match lower forecasts.
What could damage it
A collapse in the performance or relationship with a major independent distributor could cause a substantial, sudden reduction in total sales.
The company relies heavily on independent distributors to manage marketing and local sales in key international territories. Because these distributors hold inventory and control access to local hospital networks, a failure by a distributor—or the loss of a significant contract—removes the company's primary interface with the end-customer.
If a major distributor underperforms, the company cannot easily pivot, potentially leading to a sharp drop in realized demand that is outside of the company's direct control.
About STAAR Surgical Company
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, and sells phakic implantable lenses for the eye and accessory delivery systems to deliver the lenses into the eye. The company offers implantable collamer lens product family (ICLs) comprising EVO ICL, EVO+ ICL, EVO Visian ICL, and EVO Viva ICL for use in refractive surgery for the treatment of visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It serves health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as ophthalmologists. The company sells its products directly through its sales representatives in Japan, the United States, Germany, Spain, Singapore, Canada, and the United Kingdom, as well as through representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.